Study #2019-0591
Phase 1b Study of Venetoclax in Combination with Intensive Induction and Consolidation Chemotherapy in Treatment Naive Subjects with Acute Myelogenous Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Venetoclax, Daunorubicin, Cytarabine
Description
This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). The drugs involved in this study are: - Venetoclax - Daunorubicin - Cytarabine
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
I
Physician name:
Marina Konopleva
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.